Generics Makers Denied In Diabetes Drug Patent Suit
The ruling dealt a blow to patent challengers Mylan Pharmaceuticals and Alphapharm, both of which had challenged the patent for the active ingredient in the drug.
“Takeda has confidence in its patents," said Mr. Seiji Hakoda, general manager of the Intellectual Property Department of Takeda. "Because innovation is critical to...
To view the full article, register now.